08.07.20 ijBio Portfolio

Pharm Involved.

$1,000,000 on 12.06.20 Changes for 08.07.20:

AstraZeneca (AZN) $51,3 $54,2 (+5.6%) $105,600

Inovio (INO) $13,2 $23,5 (+78%) $178,000

Moderna (MRNA)$61,5 $61,6 (-0.2%) $99,800

Abbot (ABT) $88,5 $92,6 (+4.6%) $104,600

Gilead (GILD) $72,5. $75,6 (+4.3%) $104,300

Adaptive (ADPT) $42,2.  $48,8 (+15.6%) $115,600

CytoDyn (CYDY) $3,12 $5,34 (+71.1%) $171,100

AbbVie (ABBV) $92,2 $99,3 (+7.7%) $107,700

Arcus (RCUS) $27,3 $25,3 (-7.3%) $92,700

Sorrento (SRNE) $4,6  $7,3 (+58,7%) $158,700

At close 08.07.20= $1,238,100 (-1.46%)

per million dollars at 10% per share.

previous day

At close 07.07.20= $1,256,400 (+1,34%)

At close 06.07.20= $1,239,700 (+1,6%)

At close 02.07.20= $1,220,500

during the week 26-03.06.2020: -4,6%

At close 26.06.20= $1,279,600

during the week 19-26.06.2020:+21%

At close 19.06.20= $1,057,700

during the week 12-19.06 +5,7%

12.06.20 = $1,000,000

Global Communication Platforms portfoilio

--

Portfolio News:

Moderna signs on for another COVID-19 vaccine manufacturing deal

Industry Analysts Just Upgraded Their Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Revenue Forecasts By 12%

Moderna and ROVI Announce Collaboration for OUS Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate

3 Top Biotech Stocks to Watch in July

AstraZeneca’s Wins FDA Priority Review For Heart Drug Brilinta

3 Stocks I'll Be Buying When the Market Crashes Again

Prominent plaintiffs' firms sought government bailout to stay afloat

BRILINTA Granted FDA Priority Review for the Reduction of Subsequent Stroke in Patients Who Had an Acute Ischemic Stroke or Transient Ischemic Attack

Kymera Therapeutics And Sanofi Enter Into Strategic Partnership To Advance Novel Protein Degrader Therapies To Patients

FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for Second-Line Treatment of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

CLASS ACTION UPDATE for SRNE, WFC and ENDP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

In the Race to a Coronavirus Vaccine, Buy Moderna Stock or Inovio Stock?

Gilead to deliver more remdesivir to Europe from autumn - WiWo

Gilead to deliver more remdesivir to Germany, Europe from the Fall - WiWo

How Much Of AstraZeneca PLC (LON:AZN) Do Institutions Own?

Nonprofits urge Johnson & Johnson to halt sales of Baby Powder globally

Gilead begins testing inhalable form of remdesivir for COVID-19

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sorrento Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SRNE

Can This Coronavirus Stock Soar 230%? 5-Star Analyst Thinks So

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Sorrento Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 27, 2020 - SRNE

Covid-19 Research Update: The Stars and the Question Marks

Infojet Club

With help but without the assistance of Yahoo Finance

Advertise With Us